Is Mineralys Therapeutics, Inc. (MLYS) a Buy, Sell, or Hold?
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$27.28 USD
-$0.31 (-1.12%)
- Volume
- 567.55K
- Average Volume
- 1.57M
- Market Capitalization
- $1.81B
- P/E Ratio
- -13.31
- Dividend Yield
- 0.00%
- Price Target
- $43.00
- Year High
- $47.65
- Year Low
- $12.59
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $44.33
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jon Congleton |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | MLYS |
| CUSIP | 603170101 |
| CIK | 0001933414 |
| Web | https://mineralystx.com |
| Phone | 888-378-6240 |
| Currency | USD |
| Employees | 76 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 44.33 |
| Quick Ratio | 44.33 |
| Cash Ratio | 7.66 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.65 |
| Price / Cash Flow | -13.26 |
| Price / Book | 3.54 |
Price Target and Rating
| Average Stock Price Forecast | $43.00 |
| High Stock Price Forecast | $56.00 |
| Low Stock Price Forecast | $30.00 |
| Forecast Upside/Downside | -36.56% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 8 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.29 |
| Trailing P/E Ratio | -13.31 |
| PEG Ratio | -0.20 |
| P/E Growth | -0.20 |
| Net Income | $-154.65M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -27.92% |
| Return on Assets | -23.25% |
Financials Score
| AltmanZ Score | 76.04 |
| Piotroski Score | 2.00 |
| Working Capital | 637.75M |
| Total Assets | 652.86M |
| Ebit | -151.78M |
| Market Cap | 1.88B |
| Total Liabilities | 14.72M |
Poll Results
About Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock
Mineralys Therapeutics, Inc. (MLYS) is a pioneering biopharmaceutical company currently advancing through clinical trials. Its primary focus lies in creating innovative treatments for high blood pressure and its related cardiovascular complications. The company's leading investigational drug is lorundrostat. This exclusive, orally administered compound functions as a highly targeted aldosterone synthase inhibitor, specifically being developed to address difficult-to-treat cases of uncontrolled or resistant hypertension. Established in 2019, Mineralys Therapeutics operates from its headquarters in Radnor, Pennsylvania. ...
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision
2026-06-23 17:19:01
This clinical-stage biotech focused on hypertension therapies reported a notable insider sale amid strong one-year stock performance.
2026-06-14 10:00:00
– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –
2026-06-11 03:22:10
Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
2026-06-08 16:05:00
RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami on June 8-10, 2026.
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
2026-06-08 16:05:00
RADNOR, Pa. , June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami on June 8-10, 2026.
2026-06-08 07:00:00
Late-breaking presentation reports a proteomic analysis of heart failure biomarkers during lorundrostat treatment Late-breaking presentation reports a proteomic analysis of heart failure biomarkers during lorundrostat treatment
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
2026-06-03 06:05:00
RADNOR, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an underwritten offering of 5,660,378 shares of its common stock at a price of $26.50 per share. The aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $150.0 million. All of the securities to be sold in the offering are to be sold by Mineralys. The offering is expected to close on or about June 4, 2026, subject to the satisfaction of customary closing conditions.
2026-06-03 06:00:00
– Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met –
Frequently Asked Questions
-
What is the current Mineralys Therapeutics, Inc. (MLYS) stock price?
-
Mineralys Therapeutics, Inc.(NASDAQ:MLYS) stock price is $27.28 in the last trading session. During the trading session, MLYS stock reached the peak price of $47.65 while $12.59 was the lowest point it dropped to. The percentage change in MLYS stock occurred in the recent session was --1.12% while the dollar amount for the price change in MLYS stock was -$-0.31.
-
MLYS's industry and sector of operation?
-
The NASDAQ listed MLYS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MLYS?
-
Danielle Mahoney | Senior Vice President of Quality Assurance
Jon Congleton | President, Chief Executive Officer & Director
Brian Taylor Slingsby | Founder & Executive Director
David Rodman | Chief Medical Officer
Adam Scott Levy | Chief Financial Officer & Secretary -
How many employees does MLYS have?
-
Number of MLYS employees currently stands at 76. MLYS operates from 150 N. Radnor Chester Rd., Radnor, PA 19087, US.
-
Link for MLYS official website?
-
Official Website of MLYS is: https://mineralystx.com
-
How do I contact MLYS?
-
MLYS could be contacted at phone #888-378-6240 and can also be accessed through its website. MLYS operates from 150 N. Radnor Chester Rd., Radnor, PA 19087, US.
-
How many shares of MLYS are traded daily?
-
The average number of MLYS shares traded daily for last 3 months was 1.57M.
-
What is the market cap of MLYS currently?
-
The market value of MLYS currently stands at $1.81B with its latest stock price at $27.28